Moleculin Reaffirms Global IP Strategy with South Korean Patent Allowance
Moleculin Biotech announced a patent allowance in South Korea for its Annamycin reconstitution technology. This decision reinforces the company's extensive global intellectual property portfolio as it advances its pivotal MIRACLE trial.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed